Mylan NV has agreed to have an independent review organization monitor the prices it sets for government reimbursed products. The provision for the oversight body is included in a corporate integrity agreement the company entered as part of a settlement with the Department of Justice to resolve claims it misclassified EpiPen (epinephrine) as a generic drug to underpay Medicaid drug rebates.
Under the settlement agreement, announced on Aug. 17, Mylan will pay $465m to resolve False Claims Act complaints...






